Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre- vs Postoperative Thromboprophylaxis in Liver Resection
NCT04731558Phase 4Recruiting
- Sponsor
- Helsinki University Hospital
- Start
- Feb 2021
- Primary completion
- Feb 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of enoxaparin, tinzaparin and dalteparin in venous thromboembolism (VTE) (2 arms), sponsored by Helsinki University Hospital. Primary endpoint: Venous thromboembolisms at 30 days. Started Feb 2021; status: recruiting.
02
Drugs
enoxaparintinzaparindalteparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04731558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731558.